DBV Technologies | DBVT - Current Liabilities


DBV Technologies reported $58.5M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Amarin USD 175.14M 10.94M Sep/2026
BioCryst Pharmaceuticals USD 208.85M 13.46M Jun/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
DBV Technologies USD 58.5M 4.2M Sep/2026
Galectin Therapeutics USD 14.62M 1.98M Jun/2024
Halozyme Therapeutics USD 344.44M 18.77M Jun/2026
Incyte USD 1.31B 177.55M Jun/2026
Insmed USD 596.57M 157.83M Sep/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
United Therapeutics USD 607.8M 8.7M Jun/2026